

Glasgow





Cecilia Grierson (1859-1934)

First woman to receive a medical degree in Argentina

Founder of first nursing school in Argentina and National Obstetrics Association



**PEOPLE
MAKE
GLASGOW**

Challenges in Pulmonary Hypertension (PH)



- Congenital heart disease or PH?
- Why is this baby so sick?
- Which therapies will work?



Overview

- Physiology of pulmonary circulation
- Pathophysiology of PH
- Clinical assessment and management
- Future therapies

PRESSURE = FLOW x RESISTANCE








Fig. 1. Correlation of mean pulmonary arterial and systemic pressures with age in 51 normal term infants.

Changes in the Pulmonary Circulation during Birth-Related Events

DAVID F. TEITEL, HARRIET S. IWAMOTO, AND ABRAHAM M. RUDOLPH





Marc Humbert, M.D., Ph.D., Olivier Sitbon, M.D., and Gérald Simonneau, M.D. N Engl J Med 2004;351:1425-36.

$$PAP = PBF_{low} \times PV_{RESISTANCE}$$

$$\uparrow \text{PAP} = \text{PBF}_{\text{low}} \times \text{PVRESISTANCE}$$

INCREASED PBF

Left to right shunts
Large AVM

INCREASED PVR

Hyperviscosity

$$\uparrow \text{PAP} = \text{PBF}_{\text{low}} \times \text{PVRESISTANCE}$$

INCREASED PBF

Left to right shunts
Large AVM

INCREASED PVR

Hyperviscosity

VASCONSTRICTION

(functional)

“True” PPHN

Primary – “idiopathic”

Secondary:

e.g. Hypoxia, sepsis,
meconium aspiration, RDS,
PPROM

$$\uparrow \text{PAP} = \text{PBF}_{\text{low}} \times \text{PVRESISTANCE}$$

INCREASED PBF

Left to right shunts
Large AVM

INCREASED PVR

Hyperviscosity

VASCONSTRICION

(functional)

"True" PPHN

Primary – "idiopathic"

Secondary:

e.g. Hypoxia, sepsis,
meconium aspiration, RDS,
PPROM

**ABNORMAL PULMONARY
VASCULATURE**

(structural)

Congenital diaphragmatic hernia

Chronic lung disease of prematurity /BPD

Alveolar capillary dysplasia- MPV

? PH associated with trisomy 21

$$\uparrow \text{PAP} = \text{PBF}_{\text{low}} \times \text{PV RESISTANCE}$$

INCREASED PBF

Left to right shunts
Large AVM

INCREASED PVR

Hyperviscosity

VASCONSTRICTION

(functional)

“True” PPHN

Primary – “idiopathic”

Secondary:

e.g. Hypoxia, sepsis,
meconium aspiration, RDS,
PPROM

ABNORMAL PULMONARY VASCULATURE

(structural)

Congenital diaphragmatic hernia

Chronic lung disease of prematurity /BPD

Alveolar capillary dysplasia- MPV

? PH associated with trisomy 21

Increased pulmonary venous pressure:

Pulmonary vein stenosis



LV dysfunction

Obstructed left heart


Abnormal pulmonary vascular structure in congenital diaphragmatic hernia (CDH)


CDH

Controls













RV dilatation and hypertrophy in PH




RV Diastolic dysfunction in PH: Tissue Doppler Imaging



Control infant – RV




RV in PH





- Reduced systolic velocities
- Loss of diastolic E' velocity

Right Ventricular Diastolic Function Measured by Tissue Doppler Imaging Predicts Early Outcome in Congenital Diaphragmatic Hernia


Florian Moenkemeyer, MD; Neil Patel, MD



LV dysfunction in PH: speckle tracking echocardiography




Ventricular strain in the RV and LV in CDH in first 48 hours of life



Early Postnatal Ventricular Dysfunction Is Associated with Disease Severity in Patients with Congenital Diaphragmatic Hernia

Neil Patel, MD¹, Anna Claudia Massolo, MD², Anshuman Paria, MBBS¹, Emily J. Stenhouse, MBChB³, Lindsey Hunter, MRCPCH⁴, Emma Finlay, BSE⁴, and Carl F. Davis, FRCS⁵



Why is there LV dysfunction in pulmonary hypertension?

Secondary to RV dysfunction:

○ **Ventricular interdependence:**




- Shared muscle fibres
- Shared septum
- Shared pericardium

Primary LV dysfunction

- **Transitioning LV at birth** (acute increase in afterload)
- **Hypoxia, acidosis**
- **Fetal LV hypoplasia (CDH)**

Severe left diaphragmatic hernia limits size of fetal left heart more than does right diaphragmatic hernia


F. A. BYRNE*, R. L. KELLER†, J. MEADOWS*, D. MINIATI‡§, M. M. BROOK*,
N. H. SILVERMAN* and A. J. MOON-GRADY*§




GA: 16-37 weeks
N = 171 L CDH
N = 17 R CDH


Severity based on lung volumes:
Severe: LHR < 1, liver up
Moderate: LHR > 1
Mild: liver down


Ultrasound Obstet Gynecol 2015; 46: 688–694





Ventricular function and outcome in CDH







A clinical definition of PH in neonates: “clinically significant pulmonary hypertension”



1. ↑ PAP / PVR
2. Right-to-left shunting
3. Cardiac dysfunction (RV and LV)

- *Hypoxemia*
- *Acidosis*
- *Systemic hypotension*

Assessment of clinical significance of PH



Oxygenation / oxygen delivery	PVR / PAP	CARDIAC FUNCTION
Arterial oxygen saturations, SaO ₂ (post ductal)	Pre-post ductal saturations	Systemic Blood Pressure: pulse pressure
PaO ₂	Echocardiographic assessment: <ul style="list-style-type: none"> • Tricuspid regurgitation velocity • PDA shunting pattern • Time to peak velocity in pulmonary artery • Septal shape 	Echocardiographic assessment: <ul style="list-style-type: none"> • “Eyeballing” from 2d loops • Quantitative measures: <ul style="list-style-type: none"> ➤ Tissue Doppler imaging ➤ Speckle tracking echocardiography
Lactate		
Venous oxygen saturation (SVO ₂)		

Estimation of RV systolic pressure (PAP) using Tricuspid regurgitation velocity




$$\Delta P = 4v^2$$


Use of PDA flow to assess pulmonary artery pressure



PAP < SBP



PAP = SBP



PAP > SBP


Targeted treatment of “clinically-significant PH”

1. **Treat underlying cause** e.g. hypoxia, sepsis


2. **REDUCE PVR** (if elevated)
 - I. Optimize sedation, acid base,
 - II. Optimize ventilation
 - III. Pulmonary vasodilator therapy

3. **Support cardiac function**
 1. Improve systolic and diastolic RV and LV function
 2. Maintain ductus using PGE₁
 3. ECMO

Lung volume and PVR



Targeted Pulmonary vasodilator therapies



Inhaled Nitric Oxide, RCT evidence:

- **Term “PPHN”:** Improves oxygenation and **reduces death/ECMO**
- **In preterm infants: no evidence of benefit**, except in **PPROM** (prolonged preterm rupture of membranes)
- **CDH-PH:** Improves oxygenation. **No reduction in death or ECMO**

Inhaled Nitric Oxide Use in Neonates With Congenital Diaphragmatic Hernia





FIGURE 2


Trends in nitric oxide use, ECMO use, rate of repair, and mortality for 1713 infants with CDH at 33 PHIS hospitals, 2003 to 2011.

- 57% received iNO
- Median DAILY charge for iNO was \$5753
- Estimated total cohort iNO charges \$81 million

Figure 3. Association Between Inhaled Nitric Oxide (iNO) Use, Center, and Mortality $P = .01$ for Trend




Overall, there was a positive association between the trend of iNO use and mortality by center.



Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia


Florian Kipfmüller MD¹  | Lukas Schroeder MD¹ | Christoph Berg MD² |
Katrin Heindel MD¹ | Peter Bartmann MD, PhD¹ | Andreas Mueller MD¹



11 responders

15 non-responders

DOES LV DYSFUNCTION ACCOUNT FOR NON-RESPONSE TO PULMONARY VASODILATORS?



CoDiNOS trial (Europe)

Population:

Infants with CDH & PH day 0-7 of life


Intervention:

Randomised to iNO or IV sildenafil

Primary Outcomes:

- Incidence of PH on day 14 of life









Milrinone
(PDE3 inhibitor)

Use of Milrinone to Treat Cardiac Dysfunction in Infants with Pulmonary Hypertension Secondary to Congenital Diaphragmatic Hernia:

		Duration of milrinone therapy		
		pre	12-24 h post	48-72 h post
PDA flow velocity, m/s	left to right	0.8 (1.1)	0.8 (0.4)	0.5 (0.13)
	right to left	1.9 (0.6)	1.3 (0.1)	1.1 (0.3)
FiO ₂		0.55 (0.19)	0.47 (0.25)	0.47 (0.43)
Mean airway pressure, cm H ₂ O		11.8 (4.1)	10.3 (5.8)	8.6 (1.7)
OI		10.6 (5.6)	7.9 (6.2) *	5.1 (2.6)*, **
Mean BP, mm Hg		52.7 (4.3)	53.7 (11.5)	51 (7.3)
Systolic BP, mm Hg		72.6 (6.3)	75 (20.7)	67 (9.9)
Diastolic BP, mm Hg		42.8 (4.2)	43 (6.9)	43 (6.3)





Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial






Figure 4. OI (median, 95% CI) during the first 72 hours of trial treatment. No difference was observed between the bosentan and placebo groups. *Not all patients had complete data available for all time points. *BL*, baseline.

Prostaglandin E1

- Maintains PDA as “blow-off valve” for pressure-loaded RV
- May act as pulmonary vasodilator
- Use early to maintain PDA if:
 1. *RV dilated / dysfunctional and..*
 2. *PAP = or > systemic BP and..*
 3. *PDA closing or closed*



Targeted therapy of PAP and cardiac dysfunction








Fig. 2. Mean \pm SD change in blood pressure (mmHg) after birth in immediate cord clamping (ICC) and intact cord resuscitation (ICR) groups. * $p < 0.05$ for comparison between groups.

Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia



Russo FM, *et al. Thorax* 2016;**71**:517–525.



The International Congenital Diaphragmatic Hernia Symposium

Thanks to

Staff and patients of the:
Royal Hospital for Children, Glasgow
Royal Children's Hospital Melbourne

Claudia Massolo
Florian Moenkemeyer
Lindsey Hunter
CDH UK
CDH Euroconsortium
CDH International Registry

